ReviewDrugs in context2022
Relationship between breakthrough cancer pain, background cancer pain and analgesic treatment - case series and review of the literature.
Review in Drugs in context, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- Changes in the consumption of immediate-release fentanyl between 2018 and 2022 in the province of Santa Cruz de Tenerife after the implementation of regulatory measures by health authorities.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Breakthrough cancer pain management (BTcP)-gap analysis of the current Australian landscape.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Relationship between morphine rescue dose and respiratory safety during breakthrough cancer pain in lung cancer patients treated with high-dose opioids.American journal of cancer research · 2026Article
- Cancer pain: molecular mechanisms and management.Molecular biomedicine · 2025Review
- Breakthrough and Episodic Cancer Pain from a Palliative Care Perspective.Current oncology (Toronto, Ont.) · 2023Article
- Personalized Medicine in Cancer Pain Management.Journal of personalized medicine · 2023Review
- Once again... breakthrough cancer pain: an updated overview.Journal of anesthesia, analgesia and critical care · 2023Review
- Fentanyl in cancer pain management: avoiding hasty judgments and discerning its potential benefits.Drugs in context · 2023Review
- Multidisciplinary approach, continuous care and opioid management in cancer pain: case series and review of the literature.Drugs in context · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The assessment and treatment of breakthrough cancer pain (BTcP) remain a major challenge in medicine due to its high impact on several aspects of health-related quality of life. BTcP should be carefully monitored in all cancer care settings by a multidisciplinary team to provide an appropriate and personalized clinical approach. The aim of this paper is to provide healthcare professionals involved in cancer pain management with a review of the relevant literature on the relationship between background cancer pain and BTcP which, by definition, occurs despite adequately controlled background cancer pain. The clinical cases presented contribute to a better understanding of this issue and underline its impact in daily clinical practice. This article is part of the Management of breakthrough cancer pain Special Issue: https://www.drugsincontext.com/special_issues/management-of-breakthrough-cancer-pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.